Comparing efficacy of two different drugs in management of oral lichen planus
- Conditions
- Health Condition 1: L438- Other lichen planus
- Registration Number
- CTRI/2024/07/070275
- Lead Sponsor
- avneet Singh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients who are diagnosed case of oral lichen planus with or without skin lesions .
2. Both sexes - Male and Female.
3. Age- More than 18 years and less than 60 years
1. Age less than 18 years or more than 60 years.
2. Pregnancy, those female patients who are planning for pregnancy in next one month and lactation.
3. Patients unwilling to give consent to be part of trial.
4. Patients with active or latent TB.
5. Patients with anemia, liver disease, kidney disease, GI disease ( diverticulitis, perforation, ulcers ), respiratory disease ( ILD, COPD, pulmonary edema )
6. Patients with malignancies or lymphoproliferative disorders.
7. Patients on potent immunosuppressants, biological DMARDS, H/O organ transplant.
8. Patients with deranged lipid profile.
9. H/O recent live vaccination.
10. Family history of melanoma/non melanoma skin disorders.
11. Alcohol intake, tobacco and smoking.
12. Obesity.
13. H/o any thromboembolic event, cardiovascular disease, stroke.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome include evaluation and assessment of therapeutic response of methotrexate and tofacitinib in oral lichen planus according to Thongprasom score.Timepoint: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, Follow up period of 3 months
- Secondary Outcome Measures
Name Time Method Secondary outcome include safety profile and tolerability of oral methotrexate and oral tofacitinib in the treatment of oral lichen planus.Timepoint: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, follow up period of 3 months